MA54283A - Pyrazoles utilisés utilisés comme modulateurs de l'hémoglobine - Google Patents
Pyrazoles utilisés utilisés comme modulateurs de l'hémoglobineInfo
- Publication number
- MA54283A MA54283A MA054283A MA54283A MA54283A MA 54283 A MA54283 A MA 54283A MA 054283 A MA054283 A MA 054283A MA 54283 A MA54283 A MA 54283A MA 54283 A MA54283 A MA 54283A
- Authority
- MA
- Morocco
- Prior art keywords
- pyrazoles
- hemoglobin modulators
- hemoglobin
- modulators
- pyrazoles used
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862772815P | 2018-11-29 | 2018-11-29 | |
US201962915784P | 2019-10-16 | 2019-10-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA54283A true MA54283A (fr) | 2022-03-09 |
Family
ID=68807213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA054283A MA54283A (fr) | 2018-11-29 | 2019-11-26 | Pyrazoles utilisés utilisés comme modulateurs de l'hémoglobine |
Country Status (22)
Country | Link |
---|---|
US (3) | US11014908B2 (fr) |
EP (1) | EP3886984A1 (fr) |
JP (1) | JP2022510628A (fr) |
KR (1) | KR20210097161A (fr) |
CN (1) | CN113329789A (fr) |
AU (1) | AU2019387290A1 (fr) |
BR (1) | BR112021009057A2 (fr) |
CA (1) | CA3121139A1 (fr) |
CO (1) | CO2021006924A2 (fr) |
CR (1) | CR20210284A (fr) |
CU (1) | CU20210044A7 (fr) |
DO (1) | DOP2021000103A (fr) |
EC (1) | ECSP21037191A (fr) |
IL (1) | IL283408A (fr) |
MA (1) | MA54283A (fr) |
MX (1) | MX2021006095A (fr) |
PE (1) | PE20211592A1 (fr) |
PH (1) | PH12021551035A1 (fr) |
SG (1) | SG11202104585YA (fr) |
TW (2) | TWI736037B (fr) |
UY (1) | UY38488A (fr) |
WO (1) | WO2020109994A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20211592A1 (es) * | 2018-11-29 | 2021-08-18 | Pfizer | Pirazoles como moduladores de la hemoglobina |
US11597770B2 (en) | 2020-01-24 | 2023-03-07 | Pfizer Inc. | Anti-E-selectin antibodies, compositions and methods of use |
CN112079774A (zh) * | 2020-10-17 | 2020-12-15 | 甘肃天后光学科技有限公司 | 软性隐形眼镜用蓝光吸收剂、其制备方法及应用方法 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
US7169797B2 (en) | 2003-02-14 | 2007-01-30 | Abbott Laboratories | Protein-tyrosine phosphatase inhibitors and uses thereof |
US20040167188A1 (en) | 2003-02-14 | 2004-08-26 | Zhili Xin | Protein-tyrosine phosphatase inhibitors and uses thereof |
EP1760071A4 (fr) | 2004-06-23 | 2008-03-05 | Ono Pharmaceutical Co | Composé ayant une activité de liaison aux récepteurs s1p et utilisation de celui-ci |
TW200606133A (en) | 2004-06-30 | 2006-02-16 | Sankyo Co | Substituted benzene compounds |
JP2007176799A (ja) | 2005-12-27 | 2007-07-12 | Sankyo Co Ltd | 置換ベンゼン化合物を含有する医薬 |
US8039442B2 (en) | 2007-07-18 | 2011-10-18 | Glycomimetics, Inc. | Compounds and methods for treatment of sickle cell disease or complications associated therewith |
WO2011015524A2 (fr) | 2009-08-03 | 2011-02-10 | Bayer Cropscience Ag | Dérivés dhétérocycles fongicides |
CN102206172B (zh) | 2010-03-30 | 2015-02-25 | 中国医学科学院医药生物技术研究所 | 一组取代双芳基化合物及其制备方法和抗病毒应用 |
JP2013525476A (ja) * | 2010-05-04 | 2013-06-20 | ファイザー・インク | Alk阻害剤としての複素環式誘導体 |
JP5792819B2 (ja) | 2010-09-14 | 2015-10-14 | エクセリクシス, インク. | Pi3k−デルタの阻害剤ならびにそれらの使用法および製造法 |
WO2012129562A2 (fr) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Composés et procédés pour l'induction de la chondrogenèse |
US9012450B2 (en) | 2011-12-28 | 2015-04-21 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
PL2797416T3 (pl) | 2011-12-28 | 2017-12-29 | Global Blood Therapeutics, Inc. | Podstawione związki benzaldehydowe i sposoby ich zastosowania do zwiększania natlenienia tkanek |
MY191087A (en) | 2013-03-15 | 2022-05-30 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
EA201591426A1 (ru) | 2013-03-15 | 2016-02-29 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
PE20151907A1 (es) | 2013-03-15 | 2016-01-20 | Global Blood Therapeutics Inc | Compuestos y usos de estos para la modulacion de la hemoglobina |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
KR20190041548A (ko) | 2013-03-15 | 2019-04-22 | 글로벌 블러드 테라퓨틱스, 인크. | 헤모글로빈 조정을 위한 화합물 및 이의 용도 |
US20140271591A1 (en) * | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compositions and methods for the modulation of hemoglobin (s) |
US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9248199B2 (en) * | 2014-01-29 | 2016-02-02 | Global Blood Therapeutics, Inc. | 1:1 adducts of sickle hemoglobin |
EP3157904B1 (fr) | 2014-06-20 | 2020-11-18 | Institut Pasteur Korea | Composés anti-infectieux |
WO2016043849A2 (fr) | 2014-07-24 | 2016-03-24 | Global Blood Therapeutics, Inc. | Composés pour traiter le syndrome de détresse respiratoire aigu ou son effet négatif |
EP3215514B1 (fr) | 2014-11-03 | 2018-11-21 | F. Hoffmann-La Roche AG | Inhibiteurs de bace1 |
EP3218380B1 (fr) | 2014-11-16 | 2021-03-17 | Array Biopharma, Inc. | Préparation d'une forme cristalline d'hydrogénosulfate de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
MA43373A (fr) | 2015-12-04 | 2018-10-10 | Global Blood Therapeutics Inc | Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde |
EP3472150A1 (fr) | 2016-06-17 | 2019-04-24 | Fronthera U.S. Pharmaceuticals LLC | Composés modificateurs d'hémoglobine et leurs utilisations |
WO2018035072A1 (fr) | 2016-08-15 | 2018-02-22 | Purdue Research Foundation | Dérivés d'aminoisoquinoléine substitués en position 4 |
PE20211592A1 (es) * | 2018-11-29 | 2021-08-18 | Pfizer | Pirazoles como moduladores de la hemoglobina |
-
2019
- 2019-11-26 PE PE2021000762A patent/PE20211592A1/es unknown
- 2019-11-26 TW TW108142940A patent/TWI736037B/zh not_active IP Right Cessation
- 2019-11-26 MA MA054283A patent/MA54283A/fr unknown
- 2019-11-26 WO PCT/IB2019/060171 patent/WO2020109994A1/fr active Application Filing
- 2019-11-26 CU CU2021000044A patent/CU20210044A7/es unknown
- 2019-11-26 TW TW110125518A patent/TW202140452A/zh unknown
- 2019-11-26 AU AU2019387290A patent/AU2019387290A1/en not_active Abandoned
- 2019-11-26 JP JP2021529740A patent/JP2022510628A/ja active Pending
- 2019-11-26 SG SG11202104585YA patent/SG11202104585YA/en unknown
- 2019-11-26 KR KR1020217020051A patent/KR20210097161A/ko not_active Application Discontinuation
- 2019-11-26 CN CN201980090794.6A patent/CN113329789A/zh active Pending
- 2019-11-26 EP EP19816457.6A patent/EP3886984A1/fr not_active Withdrawn
- 2019-11-26 US US16/695,709 patent/US11014908B2/en active Active
- 2019-11-26 BR BR112021009057-6A patent/BR112021009057A2/pt not_active Application Discontinuation
- 2019-11-26 CA CA3121139A patent/CA3121139A1/fr not_active Abandoned
- 2019-11-26 MX MX2021006095A patent/MX2021006095A/es unknown
- 2019-11-26 CR CR20210284A patent/CR20210284A/es unknown
- 2019-11-27 UY UY0001038488A patent/UY38488A/es unknown
-
2021
- 2021-04-12 US US17/227,819 patent/US11702405B2/en active Active
- 2021-05-05 PH PH12021551035A patent/PH12021551035A1/en unknown
- 2021-05-24 IL IL283408A patent/IL283408A/en unknown
- 2021-05-25 EC ECSENADI202137191A patent/ECSP21037191A/es unknown
- 2021-05-26 DO DO2021000103A patent/DOP2021000103A/es unknown
- 2021-05-26 CO CONC2021/0006924A patent/CO2021006924A2/es unknown
-
2023
- 2023-05-24 US US18/322,844 patent/US20230382892A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TWI736037B (zh) | 2021-08-11 |
PE20211592A1 (es) | 2021-08-18 |
US11702405B2 (en) | 2023-07-18 |
IL283408A (en) | 2021-07-29 |
WO2020109994A1 (fr) | 2020-06-04 |
MX2021006095A (es) | 2021-07-06 |
US11014908B2 (en) | 2021-05-25 |
TW202033513A (zh) | 2020-09-16 |
CU20210044A7 (es) | 2022-01-13 |
JP2022510628A (ja) | 2022-01-27 |
KR20210097161A (ko) | 2021-08-06 |
US20220348555A1 (en) | 2022-11-03 |
DOP2021000103A (es) | 2021-07-30 |
ECSP21037191A (es) | 2021-06-30 |
CA3121139A1 (fr) | 2020-06-04 |
BR112021009057A2 (pt) | 2021-08-10 |
US20230382892A1 (en) | 2023-11-30 |
US20200172512A1 (en) | 2020-06-04 |
EP3886984A1 (fr) | 2021-10-06 |
CR20210284A (es) | 2021-07-09 |
CN113329789A (zh) | 2021-08-31 |
UY38488A (es) | 2020-06-30 |
CO2021006924A2 (es) | 2021-06-10 |
TW202140452A (zh) | 2021-11-01 |
AU2019387290A1 (en) | 2021-05-27 |
SG11202104585YA (en) | 2021-06-29 |
PH12021551035A1 (en) | 2021-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA52486A (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
MA44008A (fr) | 1,2,3-triazoles substitués utilisés comme modulateurs de nmda sélectifs de nr2b | |
EP3740478C0 (fr) | Dérivés d'imidazole fusionnés utilisés en tant qu'inhibiteurs d'il-17 | |
IL283128A (en) | 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin | |
MA47013A (fr) | Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase | |
MA54283A (fr) | Pyrazoles utilisés utilisés comme modulateurs de l'hémoglobine | |
IL292156A (en) | Transduced azacils as trmp8 modulators | |
DK3767753T3 (da) | Konnektor | |
DK3720433T3 (da) | Bis-cholin-tetrathiomolybdat til behandling af wilsons sygdom | |
MA53924A (fr) | Modulateurs de l'expression d'apol1 | |
MA51795A (fr) | Oligonucléotides pour moduler l'expression de tmem106b | |
HK1257772A1 (zh) | 增强通信網絡對終端設備位置的了解的準確性 | |
IL279820A (en) | Communication bridge | |
MA56030A (fr) | Pyrrolidinones substituées par un pyrazole utilisés comme herbicides | |
MA51645A (fr) | Modulateurs de l'expression de dnm2 | |
MA43922A (fr) | Dã‰rivã‰s d'indane utilisã‰s comme modulateurs de mglur7 | |
MA54237A (fr) | Composition attractive de l'espèce delottococcus aberiae | |
SG11202010971XA (en) | Small molecule modulators of mhc-i | |
FR3062793B1 (fr) | Utilisation de 2,5-dicetopiperazines en tant qu'agents cosmetiques | |
UA36982S (uk) | Крос польовий для телекомунікаційного зв'язку | |
GB201908319D0 (en) | Pionka's truffin | |
UA40066S (uk) | Горщик дитячий | |
UA38939S (uk) | Велобіг-мотоцикл дитячий | |
IT201900022908A1 (it) | Micro-fingerprint fotoniche come dispositivi anticontraffazione | |
UA38957S (uk) | Пов'язка-наліпка оклюзійна торакальна |